申请人:Dompé S.p.A.
公开号:EP2481727A1
公开(公告)日:2012-08-01
Compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (hereinafter referred to as TRPM8), having formula:
wherein
R is selected from:
- H, CN, NO2, SO2NH2, SO2NHR' and SO2NR'2, where R' is selected from linear or branched C1-C4 alkyl;
X is selected from:
- F, Cl, CH3, NH2 and OH
Y is selected from:
- O, CH2, NH and SO2
R1, R2, R3 and R4, indipendently one from the other, are selected from
- H and linear or branched C1-C4 alkyl;
Z is selected from:
- NR6 and R6R7N+, where R6 and R7 indipendently one from the other, are selected from:
• H and linear or branched C1-C4 alkyl
R5 is a residue selected from:
- H and linear or branched C1-C4 alkyl
Het is a heteroaryl group selected from
- a substituted or not substituted pyrrolyl, a substituted or not substituted N-methylpyrrolyl, a substituted or not substituted thiophenyl, a substituted or not substituted furanyl and a substituted or not substituted pyridinyl.
Said compounds are useful in the treatment of pathologies depending on TRPM8 activity such as pain, cancer, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, inflammatory conditions, urological disorders.
作为Transient Receptor Potential阳离子通道亚家族M成员8(以下简称为TRPM8)的选择性拮抗剂的化合物,其
化学式为:其中R选择自:- H、CN、
NO2、SO2NH2、SO2NHR'和SO2NR'2,其中R'选择自直链或支链的C1-C4烷基;X选择自:- F、Cl、
CH3、NH2和OHY选择自:- O、
CH2、NH和SO2R1、R2、R3和R4,独立地选择自- H和直链或支链的C1-C4烷基;Z选择自:- NR6和R6R7N+,其中R6和R7独立地选择自:• H和直链或支链的C1-C4烷基R5是选择自:- H和直链或支链的C1-C4烷基Het是选择自:- 取代或未取代的
吡咯基、取代或未取代的
N-甲基吡咯基、取代或未取代的
噻吩基、取代或未取代的
呋喃基和取代或未取代的
吡啶基。这些化合物在治疗依赖于TRPM8活性的病理病变如疼痛、癌症、炎症、缺血、神经退行性疾病、中风、精神障碍、炎症性疾病、泌尿系统疾病方面是有用的。